A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Anticoagulents

  • Coumadin®: Discontinuation of Sale

    Dr. Stephan Moll and Beth Waldron write (last updated April 28, 2020): The company making Coumadin® (warfarin sodium) tablets, Bristol-Myers Squibb (BMS), announced that it will discontinue the sale and distribution of Coumadin® (see the FDA filing here). A memo on the BMS website says: “all strengths of Coumadin® (warfarin sodium) tablets will be discontinued…

  • Coronavirus for patients: Plan your blood thinner medication refills

    Beth Waldron, MA writes….For patients on life-saving therapies like blood thinners (anticoagulants) having several weeks supply of medication on hand during the coronavirus outbreak is important not only to reduce the need to be out in public, but to ensure you have everything you need already at home if you do get sick. However, getting…

  • Antiphospholipid Syndrome: Can the New Oral Anticoagulants Be Used?

    Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin have traditionally been used. A question that comes up is whether one of the new oral anticoagulants (DOACs) can be effectively and safely…

  • New Oral Anticoagulant FDA Approved – Bevyxxa (Betrixaban)

    Stephan Moll, MD writes… On June 23, 2017, the FDA approved a 5th new oral anticoagulant for clinical use, Bevyxxa® (= Betrixaban). It is approved to prevent DVT and PE in patients who are significantly immobile during and after hospitalization for an acute medical illness. Full prescribing information: here.  FDA details: here. In the APEX study…